LEVETIRACETAM IN TREATMENT OF EPILEPSY, OWN EXPERIENCE OF APPLICATION IN ADULT PATIENTS
https://doi.org/10.21518/2079-701X-2017-10-60-64
Abstract
Basic properties of Levetiracetam (LEV) were described and own experience of its application at the dose of 500–4000 mg/day in 95 patients at the age of 17–69 years (mean age 34 ± 13 years) with various epileptic syndromes was analyzed. The overall effect of LEV made 69.1%, remission at least a year was achieved in 43.6%, in 17% – for 3 years or more. The best result was observed in juvenile myoclonic epilepsy an improvement in 83.3% of patients, remission on LEV monotherapy in 75% of patients. High efficiency was also noted in idiopathic and symptomatic generalized epilepsy – an improvement making up 78.6 and 81.3%, respectively. Idiopathic focal epilepsy LEO showed less efficiency – about 51.5%. Adverse effects were observed in 12 patients (12,8%), of which only in 3 the LEV was replaced because of the development of apathy, fatigue and the appearance of efficiency violations as a result of aggravate focal seizures. In other cases drowsiness, irritability and increased unprovoked aggression were observed, these side effects passed within the first month of treatment. The obtained results confirm the high efficacy and good tolerability of LEV.
About the Author
G. G. Toropina
Sechenov’s First Moscow State Medical University, Clinic of Nervous Diseases named after A.Ya. Kozhevnikov
Russian Federation
Russian Federation
MD
References
1. Löscher W, Hönack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur. J. Pharmacol., 1993, 232: 147-158.
2. Gower AJ, Hirsch E, Boehrer A, Noyer M, Marescaux C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res, 1995, 22: 207-213.
3. Klitgaard H, Matagne A, Gobert J, Wülfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol., 1998, 353: 191-206.
4. Noyer M, Gillard M, Matagne A, Hénichart JP, Wülfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur. J. Pharmacol., 1995, 286: 137-146.
5. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. USA, 2004, 101: 9861-9866.
6. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia, 2002, 43: 9-18.
7. Rigo JM, Hans G, Nguyen L, Rocher V, Belachew S, Malgrange B, Leprince P, Moonen G, Selak I, Matagne A, Klitgaard H. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABAand glycine-gated currents. Br. J. Pharmacol., 2002, 136: 659-672.
8. Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. Neurosci. Lett., 2001, 306: 5-8.
9. Glass GA, Stankiewicz J, Mithoefer A, Freeman R, Bergethon PR. Levetiracetam for seizures after liver transplantation. Neurology, 2005, 64: 1084-1085.
10. Zaatreh MM. Levetiracetam in porphyric status epilepticus: a case report. Clin. Neuropharmacol., 2005, 28: 243-244.
11. Brockmöller J, Thomsen T, Wittstock M, Coupez R, Lochs H, Roots I. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clin. Pharmacol. Ther., 2005, 77: 529-541.
12. Зенков Л.Р. Кеппра в лечении эпилепсии. М.: Пресс-сервис, 2007.
13. Abou-Khalil B.W. Levetiracetam Efficacy in Idiopathic Generalized Epilepsy: Long Suspected and Now Confirmed in Randomized Clinical Trials. Epilepsy Curr., 2008, 8: 16-18.
14. Verrotti A, Cerminara C, Coppola G, Franzoni E, Parisi P, Iannetti P, Aloisi P, Tozzi E, Cusmai R, Vigevano F, Chiarelli F, Curatolo P. Levetiracetam in juvenile myoclonic epilepsy: long-term efficacy in newly diagnosed adolescents. Dev. Med. Child. Neurol., 2008, 50: 29-32.
15. Alhamrani М, Babtain F, Bhatia H, Velmurugan M. Comparison of Levetiracetam With Sodium Valproate in Controlling Seizure in Patients Suffering From Juvenile Myoclonic Epilepsy. Jentashapir. J. Health Res, 2014, 5(4): e21875.
16. Sirven JI, Drazkowski JF. Levetiracetam. Wyllie’s Treatment of Epilepsy: Principles and Practice (5th ed). Eds.: Wyllie E, Cascino GD, Gidal BE, Goodkin HP. Phyladelphia: Lippincott Williams & Wilkins, 2011: 731-735.
17. Карлов В.А., Власов П.Н., Жидкова И.А. Предварительные результаты эффективности генерического леветирацетама (эпитерра) в тонотерапии эпилепсии у взрослых пациентов. Неврология, нейропсихиатрия, психосоматика, 2015, спецвыпуск 1: 36-40.
18. Vrielynck P. Current and emerging treatments for absence seizures in young patients. Neuropsychiatr. Dis. Treat., 2013, 9: 963-975.
19. Trinka E, Dobesberger J. New treatment options in status epilepticus: a critical review on intravenous levetiracetam. Ther. Adv. Neurol. Dis., 2009, 2: 79-91.
20. Atmaca MM, Orhan EK, Bebek N, Gurses C. Intravenous levetiracetam treatment in status epilepticus: A prospective study. Epilepsy Res, 2015, 114: 13-22.
21. Grosso S, Cordelli DM, Franzoni E, Coppola G, Capovilla G, Zamponi N, Verrotti A, Morgese G, Balestri P. Efficacy and safety of levetiracetam in infants and young children with refractory epilepsy. Seizure, 2007, 16: 345-350.
22. Ramantani G, Ikonomidou C, Walter B, Rating D, Dinger J. Levetiracetam: safety and efficacy in neonatal seizures. Eur. J. Paediatr. Neurol., 2011, 15: 1-7.
23. Mruk AL, Garlitz KL, Leung NR. Levetiracetam in neonatal seizures: A Review. J. Pediatr. Pharmacol. Ther., 2015, 20: 76-89.
24. Mawhinney E, Craig J, Morrow J, Russell A, Smithson WH, Parsons L, Morrison PJ, Liggan B, Irwin B, Delanty N, Hunt SJ. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology, 2013, 80: 400-405.
25. Anderson P. Lamotrigine, Levetiracetam top AEDs in pregnancy. American Epilepsy Society (AES) 2016 Annual Meeting. Poster 1.211, December, 2016.
26. Johannessen SI, Helde G, Brodtkorb E. Levetiracetam concentrations in serum and in breast milk at birth and during lactation. Epilepsia, 2005, 46: 775-777.
27. Werhahn KJ, Klimpe S, Balkaya S, Trinka E, Krämer G. The safety and efficacy of add-on levetiracetam in elderly patients with focal epilepsy: A one-year observational study. Seizure, 2011, 20: 305-311.
Review
For citations:
Toropina GG. LEVETIRACETAM IN TREATMENT OF EPILEPSY, OWN EXPERIENCE OF APPLICATION IN ADULT PATIENTS. Meditsinskiy sovet = Medical Council. 2017;(10):60-64. (In Russ.) https://doi.org/10.21518/2079-701X-2017-10-60-64
Views:
890
Email this article 